All News

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which could affect how patients are treated for cancer.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

The elimination of the program addressing LGBTQ+ individuals on the national suicide hotline makes reaching specialized help harder, says Hannah Wesolowski of the National Alliance on Mental Illness.

Rising grocery prices are forcing most Americans to shift toward ultraprocessed foods, leading to increased health risks and exacerbating existing disparities, particularly among underserved communities.

Lorna Warwick, CEO of the Lymphoma Coalition, highlights findings underscoring the vital role of clinician communication in managing adverse effects and supporting patient confidence in lymphoma and chronic lymphocytic leukemia (CLL) care.

Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.

From widening racial health disparities and abortion care restrictions to coverage losses, leadership gaps in addressing social needs, and worsening workforce shortages, the urgent need to improve health equity is underscored in the US.

Circulating tumor DNA (ctDNA) testing changes occur nearly every year, making consistent updates to National Comprehensive Cancer Network (NCCN) guidelines important for clinicians to make decisions on the use of these methods of testing, says Eric Lander, MD.

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.

This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.

Combining physician education with patient previsit activation increases deprescribing of diabetes medications, according to one study.

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and patient-preferred prep options, study finds.

Patients can benefit both financially and clinically by enrolling in ongoing clinical trials, said Eric Lander, MD.

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

Lorundrostat shows promise in reducing blood pressure and proteinuria in patients with hypertension and chronic kidney disease (CKD), highlighting its dual-action benefits.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

It's a critical time to spotlight the dire health disparities affecting Black Americans, from premature deaths to maternal care, and the urgent need for systemic reforms.

There was no association observed between lower income and increased fibrosis among New York City residents with metabolic dysfunction-associated steatohepatitis (MASH).

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

For patients with obesity, clinicians should move beyond a "try and fail" approach to lifestyle interventions and prioritize weight management medication when it can deliver crucial cardiovascular benefits.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.